Mesenchymal Stem Cells With Pharmacological Combinations Necessary to Maximize Retinal Photoreceptor, Outer and Inner Nuclear Layers Rescue.
Srivastava GK., Singh AK.
Animal Study, published in Cell Biol Int (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Biol Int (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41293972
- DOI
- 10.1002/cbin.70106
Abstract (original English)
The rising prevalence of retinal diseases underscores the need for personalized neuroprotection strategies. Mesenchymal stem cells (MSCs) exhibit paracrine neuroprotective potential and are used clinically when transplantation is unnecessary. This study evaluated MSC-mediated photoreceptor rescue and its enhancement using clinically relevant drugs; nicotinamide (NIC), vasoactive intestinal peptide (VIP), retinoic acid (ATRA), or their combination. Optimizing and personalizing treatments in accordance to retinal damage severity maximizes photoreceptor rescue, offering a targeted approach to retinal disease management. Adipose-derived MSCs were cocultured with spontaneously degenerating neuroretina explants for 6 days. VIP (5 µM), NIC (10 mM), and ATRA (5 µM) were applied individually and in combination. Photoreceptor recovery and structural changes in the inner limiting membrane (ILM), outer nuclear layer (ONL), and inner nuclear layer (INL) were assessed using Toluidine, Rhodopsin immunofluorescence, and DAPI staining. MSCs alone improved photoreceptor, ILM, ONL, and INL recovery compared to the control. However, combining VIP, NIC, and ATRA led to greater improvement, with NIC being the most effective single treatment. The combination of VIP and NIC preserved retinal structure better than VIP, NIC, and ATRA together, although none fully restored the original structure. Persona
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.